Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22944628 | 0.85 | NAMPT (0.48) | NAMPTPTPN1PTPN2PTPN6USP30 | |
| SCHEMBL6352947 | 0.85 | MAPK1 (0.49) | NAMPTKDM4EPKMUSP30 | |
| SCHEMBL21713264 | 0.84 | PTPN1 (0.55) | NAMPTPTPN1PTPN2KDM4EPKM | |
| SCHEMBL22944329 | 0.81 | TNK2 (0.49) | NAMPTUSP30 | |
| SCHEMBL31649256 | 0.80 | NR1H2 (0.49) | NAMPTPTPN1PTPN2PTPN6KDM4E | |
| SCHEMBL29197658 | 0.79 | ESR2 (0.55) | NAMPTPTPN1PTPN2PTPN6MAPT | |
| SCHEMBL21425206 | 0.78 | MAPT (0.50) | NAMPTPTPN1PTPN2PTPN6USP30 | |
| SCHEMBL21743090 | 0.78 | PTPN1 (0.48) | NAMPTPTPN1PTPN2PTPN6KDM4E | |
| SCHEMBL22945237 | 0.78 | MEN1 (0.51) | NAMPTPTPN1PTPN2PTPN6 | |
| SCHEMBL19459096 | 0.78 | ESR2 (0.45) | NAMPTPTPN1PTPN2PTPN6USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271233-A | Nilaparil manufacturing method | 特沙诺有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11629137-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3615513-B1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO INC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220041575-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO, INC. | 2022-02-10 | — | — | US | disclosed |
| US-11161834-B2 | Methods of manufacturing of niraparib | TESARO, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200055837-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | TESARO, INC. | 2020-02-20 | — | — | US | disclosed |
| CN-110753684-A | Method for producing nilapali | 特沙诺有限公司 | 2020-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055837-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | PARP2, PARP1, PARP3 | NAMPT 76/4885PTPN1 3196/4885PTPN2 2959/4885 |
| US-20220041575-A1 | METHODS OF MANUFACTURING OF NIRAPARIB | PARP2, PARP1, PARP3 | NAMPT 76/4885PTPN1 3196/4885PTPN2 2959/4885 |
| US-11161834-B2 | Methods of manufacturing of niraparib | PARP2, PARP1, PARP3 | NAMPT 76/4885PTPN1 3196/4885PTPN2 2959/4885 |
| US-11629137-B2 | Methods of manufacturing of niraparib | PARP2, PARP1, PARP3 | NAMPT 76/4885PTPN1 3196/4885PTPN2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.